BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.73−0.03 (-4.27%)
Close on Nov 18, 2026Market cap $2.15MP/E –Yield –
BioNexus Gene Lab pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
BioNexus Gene Lab's pe ratio was 670.6× on Aug 31, 2020.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2020 | Aug 31, 2020 | 670.6× | – |
See a number that looks wrong?